ImpediMed CHIA:IPD 주식 보고서 ImpediMed Limited
CHIA:IPD 주식 보고서
IPD 주식 개요 의료 기술 회사인 ImpediMed Limited는 미국과 유럽에서 생체 임피던스 분광법(BIS) 기술 의료 기기를 제조 및 판매하는 회사입니다.
가격 내역 및 성능
다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ImpediMed 과거 주가 현재 주가 AU$0.054 52주 최고치 AU$0.16 52주 최저치 AU$0.043 베타 2.87 11개월 변경 -10.00% 3개월 변경 사항 -6.90% 1년 변경 사항 -61.43% 33년 변화 -69.14% 5년 변화 -73.00% IPO 이후 변화 -70.81%
최근 뉴스 및 업데이트
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023) Aug 30
Forecast to breakeven in 2027 Aug 29
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 23 더 많은 업데이트 보기
ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024 Oct 15
ImpediMed Limited, Annual General Meeting, Nov 19, 2024 Sep 27
Board Member recently bought AU$73k worth of stock Sep 03
Full year 2024 earnings released: EPS: AU$0 (vs AU$0.011 loss in FY 2023) Aug 30
Forecast to breakeven in 2027 Aug 29
ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Aug 23
Forecast to breakeven in 2026 Jul 30 ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis
ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director Jun 08
New minor risk - Market cap size Jun 04
Independent Non-Executive Director recently bought AU$50k worth of stock May 15
ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024 Apr 20
ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting Apr 11
Independent Non-Executive Director recently bought AU$100k worth of stock Mar 28
Independent Non-Executive Director recently bought AU$90k worth of stock Mar 02
No longer forecast to breakeven Feb 03
High number of new and inexperienced directors Feb 01
ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024 Jan 23
Independent Non-Executive Director recently bought AU$135k worth of stock Dec 19 ImpediMed Limited Announces CFO Changes
ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023 Oct 24
ImpediMed Limited, Annual General Meeting, Nov 30, 2023 Oct 12
High number of new directors Oct 05
ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer Sep 27
Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.012 loss in FY 2022) Aug 31
ImpediMed Limited, Annual General Meeting, Sep 28, 2023 Aug 18
ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023 Jul 17
ImpediMed Limited Appoints Daniel Sharp as Director Jul 06
Executive Director recently bought AU$144k worth of stock Jun 28
Independent Non-Executive Chairman recently bought AU$82k worth of stock Jun 14
No longer forecast to breakeven May 30
MD, CEO & Director recently bought AU$52k worth of stock Apr 22
MD, CEO & Director recently bought AU$54k worth of stock Mar 31
MD, CEO & Director recently bought AU$64k worth of stock Mar 08
First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022) Feb 25
ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023 Jan 24
ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival Dec 16 Impedimed Limited Announces CEO Changes
ImpediMed Limited Announces Management Changes Nov 22
Less than half of directors are independent Nov 17
Executive Director & Interim CEO recently bought AU$164k worth of stock Nov 01
Less than half of directors are independent Oct 29
ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema Oct 27
ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022 Oct 13
ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer Oct 12
ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients Oct 05
ImpediMed Limited Announces Board Changes Aug 30
Full year 2022 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in FY 2021) Aug 30
ImpediMed Limited, Annual General Meeting, Oct 26, 2022 Aug 29
Less than half of directors are independent Jul 28
ImpediMed Limited Announces Executive Changes Jul 27 ImpediMed Limited Announces Resignation of Richard Carreon as Managing Director
ImpediMed Limited Announces Release of the New Version 4.1 Software for the SOZO Digital Health Platform Jun 02
No longer forecast to breakeven Apr 27
ImpediMed Limited to Report Q3, 2022 Results on Apr 28, 2022 Apr 22
New Bone Data Showing Strong Correlation Between ImpediMed's SOZO and DXA in Cancer Patients Presented At 39Th Annual Miami Breast Cancer Conference Mar 07
No longer forecast to breakeven Mar 05
First half 2022 earnings: EPS in line with expectations, revenues disappoint Mar 01
Now 22% undervalued Feb 15
Forecast to breakeven in 2024 Sep 23
FDA Grants Breakthrough Device Designation for ImpediMed's SOZO Digital Health Platform for Renal Failure Aug 31
Full year 2021 earnings released: AU$0.02 loss per share (vs AU$0.036 loss in FY 2020) Aug 26
Impedimed Announces Next Generation of Sozo® Digital Health Platform Software Jun 08
ImpediMed Limited Announces Official Release of SOZO Version 4.0 Software May 25
First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.026 loss in 1H 2020) Feb 23
ImpediMed Limited to Report Q2, 2021 Results on Jan 28, 2021 Jan 21
ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up Jan 12 Impedimed Limited Announces the Publication of A New Study Demonstrating That the Company's Lymphedema Prevention Program
ImpediMed Limited Secures First Commercial Heart Failure Sales Nov 18
ImpediMed Limited Announces NSW Health Further Expands Lymphoedema Prevention Program Nov 16
AstraZeneca Selects SOZO for Second Large Renal Trial Nov 09
HFSA Poster Supports HF-Dex in the Management of HF Patients Oct 04
Impedimed Limited Announces Collaboration with the Live Today Foundation to Increase Awareness and Access to Care for Cancer Patients At Risk or Suffering from Lymphedema Oct 03
Impedimed Limited Announces Contract Valued at over AUD 2 Million for its SOZO Digital Health Platform to Be Used in Clinical Trial Being Conducted for AstraZeneca Sep 30
ImpediMed Limited(ASX:IPD) dropped from S&P/ASX Emerging Companies Index Sep 21
ImpediMed Limited Auditor Raises 'Going Concern' Doubt Sep 01
Earnings released Aug 26
ImpediMed Limited to Report Q4, 2020 Results on Jul 28, 2020 Jul 21
ImpediMed Limited announced that it has received AUD 0.227339 million in funding Jul 07 주주 수익률 IPD AU Medical Equipment AU 마켓 7D 1.9% 3.8% 1.1% 1Y -61.4% 17.6% 18.3%
전체 주주 수익률 보기
수익률 대 산업: IPD 지난 1년 동안 17.6 %를 반환한 Australian Medical Equipment 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: IPD 지난 1년 동안 18.3 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is IPD's price volatile compared to industry and market? IPD volatility IPD Average Weekly Movement 10.1% Medical Equipment Industry Average Movement 9.8% Market Average Movement 8.4% 10% most volatile stocks in AU Market 17.5% 10% least volatile stocks in AU Market 3.5%
안정적인 주가: IPD 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: IPD 의 주간 변동성 ( 10% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 의료 기술 회사인 ImpediMed Limited는 미국과 유럽에서 생체 임피던스 분광법(BIS) 기술 의료 기기를 제조 및 판매하고 있습니다. 이 회사는 림프부종의 임상 평가 및 체액 상태와 조직 구성의 스냅샷을 제공하는 비침습적 BIS 기기인 SOZO, 림프부종에 대한 L-Dex 분석, 현장 체성분 분석인 BodyComp 분석, 현장 또는 치료 심부전 체액 평가를 위한 HF-Dex 분석 등을 제공합니다. 또한 건강한 개인의 체성분 분석을 위한 단일 채널 4극성 BIS 기기인 SFB7과 동물용 체액 상태 및 조직 구성을 측정하는 단일 채널 4극성(BIS) 기기인 ImpediVET도 제공합니다.
자세히 보기 ImpediMed Limited 기본 사항 요약 ImpediMed 의 수익과 매출은 시가총액과 어떻게 비교하나요? IPD 기본 통계 시가총액 AU$111.30m 수익(TTM ) -AU$19.79m 수익(TTM ) AU$10.32m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) IPD 손익 계산서(TTM ) 수익 AU$10.32m 수익 비용 AU$1.31m 총 이익 AU$9.01m 기타 비용 AU$28.80m 수익 -AU$19.79m
주당 순이익(EPS) -0.0098 총 마진 87.27% 순이익 마진 -191.78% 부채/자본 비율 0%
IPD 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
